GenSight Biologics – pharmaceutical daily

July 11, 2019 Off

GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule

The conclusion of enrollment for the REFLECT study is a milestone in the story of gene therapy for Leber Hereditary Optic Neuropathy,” commented Nancy J. Newman,

May 6, 2019 Off

GenSight Biologics to present Data from the Reverse Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)

By BusinessWire

GenSIght will present results from the REVERSE Phase III clinical trial of GS010 at the 2019 American Academy of Neurology (AAN) Annual Meeting

March 13, 2017 Off

GenSight Biologics reports €22M loss for 2016

By Dino Mustafić

GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, has reported €22.1 million loss for 2016, which is increase of loss comparing last years €13.7 million.

January 31, 2017 Off

FDA grants ODD to GenSight’s retinitis pigmentosa drug

By Dino Mustafić

GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa.